Nanobiotix S.A. (EPA:NANO)

Nanobiotix Statistics

Total Valuation

Nanobiotix has a market cap or net worth of EUR 1.33 billion. The enterprise value is 1.28 billion.

Market Cap	1.33B
Enterprise Value	1.28B

Important Dates

The last earnings date was Tuesday, March 31, 2026.

Earnings Date	Mar 31, 2026
Ex-Dividend Date	n/a

Share Statistics

Nanobiotix has 48.47 million shares outstanding. The number of shares has increased by 1.29% in one year.

Current Share Class	48.47M
Shares Outstanding	48.47M
Shares Change (YoY)	+1.29%
Shares Change (QoQ)	+0.03%
Owned by Insiders (%)	3.29%
Owned by Institutions (%)	7.41%
Float	31.11M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	40.75
PB Ratio	-15.72
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-53.23
EV / Sales	39.13
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-37.56

Financial Position

The company has a current ratio of 1.09

Current Ratio	1.09
Quick Ratio	0.95
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-0.71

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-10.00%
Return on Invested Capital (ROIC)	n/a
Return on Capital Employed (ROCE)	-105.51%
Weighted Average Cost of Capital (WACC)	7.25%
Revenue Per Employee	316,437
Profits Per Employee	-232,631
Employee Count	103
Asset Turnover	0.48
Inventory Turnover	n/a

Taxes

In the past 12 months, Nanobiotix has paid 3,000 in taxes.

Income Tax	3,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +744.64% in the last 52 weeks. The beta is 0.55, so Nanobiotix's price volatility has been lower than the market average.

Beta (5Y)	0.55
52-Week Price Change	+744.64%
50-Day Moving Average	23.91
200-Day Moving Average	15.81
Relative Strength Index (RSI)	53.43
Average Volume (20 Days)	286,837

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Nanobiotix had revenue of EUR 32.59 million and -23.96 million in losses. Loss per share was -0.50.

Revenue	32.59M
Gross Profit	32.59M
Operating Income	-10.82M
Pretax Income	-23.96M
Net Income	-23.96M
EBITDA	-9.32M
EBIT	-10.82M
Loss Per Share	-0.50

Balance Sheet

The company has 52.75 million in cash and n/a in debt, with a net cash position of 52.75 million or 1.09 per share.

Cash & Cash Equivalents	52.75M
Total Debt	n/a
Net Cash	52.75M
Net Cash Per Share	1.09
Equity (Book Value)	-84.48M
Book Value Per Share	-1.74
Working Capital	5.24M

Cash Flow

In the last 12 months, operating cash flow was -33.42 million and capital expenditures -538,000, giving a free cash flow of -33.96 million.

Operating Cash Flow	-33.42M
Capital Expenditures	-538,000
Depreciation & Amortization	1.50M
Net Borrowing	38.19M
Free Cash Flow	-33.96M
FCF Per Share	-0.70

Margins

Gross margin is 100.00%, with operating and profit margins of -33.19% and -73.52%.

Gross Margin	100.00%
Operating Margin	-33.19%
Pretax Margin	-73.51%
Profit Margin	-73.52%
EBITDA Margin	-28.60%
EBIT Margin	-33.19%
FCF Margin	n/a

Dividends & Yields

Nanobiotix does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.29%
Shareholder Yield	-1.29%
Earnings Yield	-1.80%
FCF Yield	-2.56%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2